Table 3.
Correlation between preoperative plasma albumin level and clinicopathological characteristics in pancreatic ductal adenocarcinoma patients who underwent R0 resection, n (%)
|
Characteristics
|
Preoperative plasma albumin level |
P
value
|
|
|
> 45.2 g/L, n = 85
|
≤ 45.2 g/L, n = 197
|
||
| Age in yr | 0.602 | ||
| > 60 | 42 (14.9) | 104 (36.9) | |
| ≤ 60 | 43 (15.2) | 93 (33.0) | |
| Sex | 0.699 | ||
| Male | 47 (16.7) | 104 (36.9) | |
| Female | 38 (13.5) | 93 (33.0) | |
| Clinical symptoms | 0.012 | ||
| Absent | 25 (8.9) | 32 (11.3) | |
| Present | 60 (21.3) | 165 (58.5) | |
| Diabetes | 0.458 | ||
| Absent | 58 (20.6) | 143 (50.7) | |
| Present | 27 (9.6) | 54 (19.1) | |
| Smoking status | 0.806 | ||
| Absent | 64 (22.7) | 151 (53.5) | |
| Present | 21 (7.4) | 46 (16.3) | |
| Alcohol consumption | 0.523 | ||
| Absent | 69 (24.5) | 166 (58.9) | |
| Present | 16 (5.7) | 31 (11.0) | |
| Family history of cancer | 0.832 | ||
| Absent | 82 (29.1) | 189 (67.0) | |
| Present | 3 (1.1) | 8 (2.8) | |
| Blood type | 0.169 | ||
| A | 33 (11.7) | 54 (19.1) | |
| B | 22 (7.8) | 71 (25.2) | |
| AB | 8 (2.8) | 14 (5.0) | |
| O | 22 (7.8) | 58 (20.6) | |
| Tumor location | < 0.001 | ||
| Head and neck | 24 (8.5) | 106 (37.6) | |
| Body and tail | 61 (21.6) | 91 (32.3) | |
| Approaches of open surgery | < 0.001 | ||
| Pancreaticoduodenectomy | 24 (8.5) | 106 (37.6) | |
| Distal pancreatectomy with splenectomy | 61 (21.6) | 91 (32.3) | |
| Degree of differentiation | 0.567 | ||
| Well | 8 (2.8) | 26 (9.2) | |
| Moderately | 66 (23.4) | 151 (53.5) | |
| Poorly | 11 (3.9) | 20 (7.1) | |
| Lymphovascular invasion | 0.814 | ||
| Absent | 62 (22.0) | 141 (50.0) | |
| Present | 23 (8.2) | 56 (19.9) | |
| Perineural invasion | 0.741 | ||
| Absent | 20 (7.1) | 50 (17.7) | |
| Present | 65 (23.0) | 147 (52.1) | |
| Capsular invasion | 0.673 | ||
| Absent | 16 (5.7) | 33 (11.7) | |
| Present | 69 (24.5) | 164 (58.2) | |
| Maximum tumor diameter in cm | 0.330 | ||
| > 4 | 30 (10.6) | 58 (20.6) | |
| ≤ 4 | 55 (19.5) | 139 (49.3) | |
| T stage | 0.530 | ||
| T1 | 8 (2.8) | 26 (9.2) | |
| T2 | 47 (16.7) | 112 (39.7) | |
| T3 | 30 (10.6) | 59 (20.9) | |
| Number of metastatic lymph nodes | 0.363 | ||
| Absent | 52 (18.4) | 109 (38.7) | |
| Present | 33 (11.7) | 88 (31.2) | |
| N stage | 0.127 | ||
| N0 | 52 (18.4) | 109 (38.7) | |
| N1 | 29 (10.3) | 63 (22.3) | |
| N2 | 4 (1.4) | 25 (8.9) | |
| TNM stage | 0.145 | ||
| IA | 4 (1.4) | 16 (5.7) | |
| IB | 34 (12.1) | 58 (20.6) | |
| IIA | 14 (5.0) | 35 (12.4) | |
| IIB | 29 (10.3) | 63 (22.3) | |
| III | 4 (1.4) | 25 (8.9) | |
| Adjuvant therapy | 0.003 | ||
| Absent | 26 (9.2) | 98 (34.8) | |
| Present | 59 (20.9) | 99 (35.1) | |
| Preoperative CA19-9 level in U/mL | 0.416 | ||
| > 336.4 | 26 (9.2) | 51 (18.1) | |
| ≤ 336.4 | 59 (20.9) | 146 (51.8) | |
| Preoperative plasma fibrinogen concentration in g/L | 0.006 | ||
| > 3.31 | 32 (11.3) | 109 (38.7) | |
| ≤ 3.31 | 53 (18.8) | 88 (31.2) | |
| Preoperative FAR | < 0.001 | ||
| > 0.08 | 15 (5.3) | 111 (39.4) | |
| ≤ 0.08 | 70 (24.8) | 86 (30.5) | |
FAR: Fibrinogen-to-albumin ratio; TNM: Tumor-Node-Metastasis.